

# Gliomaの遺伝子異常


2016・2・16 抄読会 Review

梅野 哲也

# 主にLow grade gliomaにおいて重要な異常


- IDH1/2
- TP53
- 1p/19q
- ATRX / TERT
- FUBPI, CIC
- BRAF

# IDH1/2 mutation




Philipp K et al. Sci  
Rep. 2015; 5: 16238.

# IDH1/2 mutation




Yan H et al. NEJM 360: 765, 2009

# IDH1/2 mutation




Parsons DW et al. Science  
321: 1808, 2008



Yan H et al. NEJM 360: 765, 2009


# IDH1/2 mutation




TCGAでのメチローム解析

IDH1mutationとGCIMPとの相関

# TP53 mutation




# 1p/19q codeletion




Translocation t(1;19)(q10;p10)

- Microsatellite 解析
- FISH 法
- MLPA 法
- SNP アレイ

# 1p/19q codeletion



| O   | N   | No. of patients at risk:                         |       |  |  |  |
|-----|-----|--|-------|--|--|--|
| 103 | 120 | 50      35      27      19      9      3      2  | ----- |  |  |  |
| 84  | 113 | 62      44      40      27      18      5      1 | ----- |  |  |  |
| 20  | 36  | 31      28      21      15      12      6      1 | ----- |  |  |  |
| 14  | 42  | 37      31      29      21      15      9      3 | ----- |  |  |  |





|  |  | Patients at risk: |    |    |    |    |
|--|--|-------------------|----|----|----|----|
|  |  | 43                | 41 | 37 | 17 | 10 |
|  |  | 50                | 47 | 42 | 24 | 5  |
|  |  | 57                | 44 | 34 | 13 | 4  |
|  |  | 51                | 42 | 30 | 13 | 3  |

Van de Bent MJ et al. JCO 2006

Cairncross G et al. JCO 2006

# ATRX mutation / TERT promotor mutation


○Teromere伸長関連変異



Gocha AR et al. Mutat Res 2013

Nabetani A et al. Biochem 2011

# ATRX mutation / TERT promotor mutation



# Mutations in FUBPI and CIC

いずれもoligodendrogliomaのexome sequence解析で新たに発見。

- FUBPI  
染色体1pに存在。mycの発現を調整。  
5/34 oligodendroglioma
- CIC  
染色体19qに存在。MAPKと関連したはたらき。  
18/26oligodendroglioma ・・・ 69%

# BRAF/KIAA1549 Fusion gene





FIGURE 1. Molecular alterations in BRAF. (A, B) FISH assay for detection of KIAA1549:BRAF fusion showing a positive (A) and a negative (B) case (white arrows). (C, D) Point mutations detected by Sanger sequencing for V600E (C) and V600K (D).

Pilocytic Aの66%  
MAPK経路に関与  
予後因子とはならない  
PXA(6%)や  
ganglioglioma(18%)にも。

# 分子診断因子とgliomaの対応


- IDH1/2 mutation : LGG, Secondary GBM
- TP53 mutation : Astrocytoma, GBM
- ATRX mutation : Astrocytic tumor
- TERT promotor mutation:Oligo,GBM
- 1p/19q codeletion : Oligo
- BRAF/KIAA fusion gene : Pilocytic A

# Low grade glioma:新たなWHO分類の方向性




# Low grade glioma:新たなWHO分類の 方向性

A Gliomas Classified According to Histologic Class and Grade



B Gliomas Classified According to Molecular Subtype



# Low grade glioma:新たなWHO分類の 方向性

Molecular information

|   | Histologic classification                                       |  |   |
|---|---|--|---|
|   | Diffuse astrocytoma   | Oligodendrogloma   | "Oligoastrocytoma" or ambiguous histology           |
| IDH-mut, 1p/19q-nondel,<br>ATRX loss      | <i>Diffuse astrocytoma, ATRX loss of expression</i>             | <i>Diffuse glioma* (oligodendrogloma phenotype), 1p/19q non-deleted, ATRX loss of expression</i> | <i>Diffuse astrocytoma, ATRX loss of expression</i> |
| IDH-mut, 1p/19q-codeleted,<br>ATRX intact | <i>Diffuse glioma (astrocytoma phenotype), 1p/19q-codeleted</i> | <i>Oligodendrogloma, 1p/19q-codeleted</i>  | <i>Oligodendrogloma, 1p/19q-codeleted</i>           |
| IDH wild type                             | <i>Diffuse astrocytoma, IDH wild type*</i>                      | <i>Diffuse glioma* (oligodendrogloma phenotype), IDH wild type*</i>                              | <i>Diffuse astrocytoma, IDH wild type*</i>          |
| Testing not performed                     | <i>Diffuse astrocytoma, NOS</i>                                 | <i>Oligodendrogloma, NOS</i>   | <i>"Diffuse glioma, NOS"</i>                        |

Louis DN et al. Brain Pathol 2014